Allianz Asset Management Gmb H Allakos Inc. Transaction History

Allianz Asset Management Gmb H

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$8.55 - $111.89 $545,472 - $7.14 Million	-63,798 Closed	0 $0
Q3 2021 Nov 10, 2021	BUY	$76.53 - $110.43 $1.69 Million - $2.44 Million	22,077 Added 52.92%	63,798 $6.75 Million
Q2 2021 Aug 16, 2021	BUY	$85.37 - $114.1 $52,844 - $70,627	619 Added 1.51%	41,721 $3.56 Million
Q1 2021 May 13, 2021	BUY	$109.73 - $153.66 $90,856 - $127,230	828 Added 2.06%	41,102 $4.72 Million
Q4 2020 Feb 16, 2021	SELL	$79.58 - $152.45 $403,948 - $773,836	-5,076 Reduced 11.19%	40,274 $5.64 Million
Q3 2020 Nov 13, 2020	SELL	$66.43 - $90.99 $336,268 - $460,591	-5,062 Reduced 10.04%	45,350 $3.69 Million
Q2 2020 Aug 14, 2020	BUY	$44.04 - $80.69 $438,242 - $802,946	9,951 Added 24.59%	50,412 $3.62 Million
Q1 2020 May 14, 2020	BUY	$44.49 - $93.39 $1.31 Million - $2.75 Million	29,488 Added 268.73%	40,461 $1.8 Million
Q4 2019 Feb 13, 2020	SELL	$66.49 - $137.73 $621,880 - $1.29 Million	-9,353 Reduced 46.01%	10,973 $1.05 Million
Q3 2019 Nov 13, 2019	BUY	$31.0 - $89.73 $250,077 - $723,851	8,067 Added 65.8%	20,326 $1.6 Million
Q2 2019 Aug 08, 2019	BUY	$36.0 - $44.73 $441,324 - $548,345	12,259 New	12,259 $531,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.